Photo from wikipedia
Sorafenib and lenvatinib are the first‐line treatments approved in hepatocellular carcinoma (HCC), but information is lacking about the relationships between their pharmacokinetics, patients pharmacogenetic profiles, adverse events (AE) and overall… Click to show full abstract
Sorafenib and lenvatinib are the first‐line treatments approved in hepatocellular carcinoma (HCC), but information is lacking about the relationships between their pharmacokinetics, patients pharmacogenetic profiles, adverse events (AE) and overall survival. We aimed to elucidate these relationships of tyrosine Kinase Inhibitors, such as sorafenib, in order to improve the design of trials testing it in combination with checkpoint inhibitors.
Keywords:
hepatocellular carcinoma;
combination;
pharmacokinetics pharmacogenetics;
pharmacogenetics sorafenib;
sorafenib patients;
patients hepatocellular
Journal Title: Liver International
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Liver International
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!